Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?

It is not clear if platelet responses are sustained after thrombopoietin receptor agonist (ar‐TPO) withdrawal in paediatric patients. A multicentre retrospective observational study was performed in children with chronic immune thrombopenia (cITP) to describe ar‐TPO tapering and withdrawal in patients who had achieved a sustained complete response to ar‐TPOs. Ten patients (eltrombopag n = 6, romiplostim n = 4) were included. Treatment withdrawal was performed after a mean tapering time of 7.6 months. Two patients relapsed (median follow‐up time of 24 months). Slow tapering and withdrawal of ar‐TPOs can be safely performed in cITP paediatric patients after achieving a sustained complete response.

[1]  Solsona María,et al.  Tapering of thrombopoietin receptor agonist in pediatric patients with chronic immune thrombocytopenia. Is it possible? , 2022, British journal of clinical pharmacology.

[2]  A. Raj,et al.  Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials , 2020, Pediatric blood & cancer.

[3]  Jae Min Lee,et al.  Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia , 2020, Yeungnam University journal of medicine.

[4]  C. Santoro,et al.  Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations. , 2019, Blood reviews.

[5]  Xiaoyan Liu,et al.  Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review. , 2019, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[6]  J. González-Porras,et al.  Use of eltrombopag for secondary immune thrombocytopenia in clinical practice , 2017, British journal of haematology.

[7]  D. Kuter,et al.  Remissions after long-term use of romiplostim for immune thrombocytopenia , 2016, Haematologica.

[8]  P. Forbes,et al.  Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study , 2016, Pediatric blood & cancer.

[9]  J. Bussel,et al.  Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. , 2015, The Lancet. Haematology.

[10]  P. Galan,et al.  Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia , 2014, American journal of hematology.

[11]  F. Roudot-thoraval,et al.  The temporary use of thrombopoietin‐receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study , 2014, British journal of haematology.

[12]  R. Marwaha,et al.  Outcome of chronic idiopathic thrombocytopenic purpura in children , 2010, Pediatric blood & cancer.

[13]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[14]  P. Visintainer,et al.  Long-Term Outcome of Chronic Idiopathic Thrombocytopenic Purpura in Children , 2004, Journal of pediatric hematology/oncology.